English | Español
Patient Daily | Apr 27, 2023

Digital therapeutics: at an inflection point
Patient Daily | Apr 27, 2023

Augmedix Secures Strategic Financing from HCA Healthcare and Redmile Group
Patient Daily | Apr 26, 2023

Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma
Patient Daily | Apr 24, 2023

Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
Patient Daily | Apr 24, 2023

Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration
Patient Daily | Apr 24, 2023

Horizon Therapeutics plc to Release First-Quarter 2023 Financial Results on May 3, 2023
Patient Daily Report | Apr 7, 2023

Holmusk CEO on NeuroBlu Database: 'Our vision was to provide the gold standard for behavioral health real-world data'
Press release submission | Jul 3, 2022

Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis

Trending
+ Technology/Innovation
Patient Daily | May 8, 2025

Medfluence attends 2025 Annual Clinical Assembly as only strategic marketing firm
+ Technology/Innovation
Patient Daily | May 7, 2025

OTO Forum 2025 highlights innovation in ENT
+ Pharmaceuticals
Patient Daily | May 8, 2025

Pacific Research Institute CEO: Hospitals are leveraging 340B's 'perverse incentives to enrich themselves'
+ Pharmaceuticals
Patient Daily | May 8, 2025

National Library of Medicine says compounded drugs like GLP-1 offer tailored alternatives to FDA-approved treatments